CRIS Current Research Information System

BON, ISABELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.055
EU - Europa 2.133
AS - Asia 740
AF - Africa 211
SA - Sud America 15
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.163
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.049
GB - Regno Unito 545
SE - Svezia 436
IT - Italia 371
CN - Cina 301
DE - Germania 264
VN - Vietnam 166
IN - India 125
IE - Irlanda 119
TG - Togo 109
UA - Ucraina 94
FR - Francia 79
SG - Singapore 77
RU - Federazione Russa 74
EE - Estonia 45
ZA - Sudafrica 44
JO - Giordania 36
BG - Bulgaria 33
NG - Nigeria 33
BE - Belgio 21
CH - Svizzera 19
CI - Costa d'Avorio 18
BR - Brasile 8
HK - Hong Kong 7
IR - Iran 7
ES - Italia 6
SC - Seychelles 6
FI - Finlandia 5
TR - Turchia 5
AU - Australia 4
JP - Giappone 4
LB - Libano 4
PT - Portogallo 4
RO - Romania 4
UZ - Uzbekistan 4
CL - Cile 3
EU - Europa 3
MX - Messico 3
NL - Olanda 3
CA - Canada 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GR - Grecia 2
NZ - Nuova Zelanda 2
PE - Perù 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
MA - Marocco 1
MD - Moldavia 1
MS - Montserrat 1
MY - Malesia 1
SI - Slovenia 1
VE - Venezuela 1
Totale 6.163
Salva come PNG Salva come JPEG
Città #
Southend 484
Fairfield 395
Chandler 337
Ashburn 256
Woodbridge 209
Seattle 184
Wilmington 170
Ann Arbor 164
Houston 164
Dong Ket 148
Princeton 138
Cambridge 133
Dublin 119
Lomé 109
Bologna 87
Florence 70
Singapore 65
Nanjing 55
Westminster 54
Jacksonville 52
Padova 49
Berlin 45
Turin 39
Amman 36
Abeokuta 33
Sofia 33
Jinan 29
Shenyang 29
San Diego 27
Beijing 26
Redmond 26
Saint Petersburg 24
Boardman 22
Hebei 22
Brussels 21
Abidjan 18
New York 18
Dearborn 16
Bremen 15
Milan 15
Des Moines 14
Nanchang 14
Tianjin 14
Jiaxing 13
Olalla 13
Bern 12
Falls Church 12
Los Angeles 12
Ningbo 11
Rome 11
London 10
Mülheim 10
Zhengzhou 10
Bühl 9
Taizhou 9
Changsha 8
Haikou 8
Hangzhou 8
Atlanta 7
Lanzhou 7
Paris 7
Phoenix 7
Taiyuan 7
Mahé 6
Chicago 5
Guangzhou 5
Monmouth Junction 5
Norwalk 5
Trabia 5
Ardabil 4
Divinópolis 4
Fuzhou 4
Helsinki 4
Hong Kong 4
Istanbul 4
Redwood City 4
Verona 4
Castenaso 3
Hyderabad 3
Kuban 3
Kunming 3
Medolla 3
Muizenberg 3
Pescara 3
Plauen 3
San Francisco 3
San Venanzo 3
São Paulo 3
Bochum 2
Boydton 2
Edinburgh 2
Frankfurt Am Main 2
Fremont 2
Geneva 2
Grottammare 2
Hefei 2
Islington 2
Kilburn 2
Maddaloni 2
Melbourne 2
Totale 4.289
Salva come PNG Salva come JPEG
Nome #
Acute onset myopericarditis as unusual presentation of primary HIV infection 182
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells 165
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection 153
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 151
Discordant resistance interpretations in multi-treated HIV-1 patients 145
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 140
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. 131
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 131
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 124
Antiretroviral molecules and cardiovascular diseases. 123
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures 120
Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. 119
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 118
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. 117
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke 117
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 116
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 114
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns 114
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 114
null 113
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 113
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 112
HIV-related mechanisms in atherosclerosis and cardiovascular diseases. 111
Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. 111
Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results 108
Effects of Antiretroviral Molecules on Survival and Gene Expression of an Osteoblast-like Cell Line 108
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy 104
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case report. 103
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 103
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 101
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 101
HIV and kidney: A dangerous liaison 100
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 100
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 99
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 97
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. 94
Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. 91
An HIV type 2 case series in Italy: A phylogenetic analysis 91
V3 net charge: additional tool in HIV-1 tropism prediction 89
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 88
Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy 84
Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? 84
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 84
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 84
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 82
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: Results from the DIVA study group 81
Significant association between statin-associated myalgia and Vitamin D deficiency among treated HIV-infected patients 78
Improving counterfactual reasoning with kernelised dynamic mixing models 77
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. 77
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study) 75
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy 74
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 73
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 71
HIV-1 gp120 impairs the differentiation and survival of cord blood CD34+ HPCs induced to the erythroid lineage. 67
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 65
Restriction Factors expression decreases in HIV-1 patients after cART 64
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 62
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. 59
HBsAg seroreversion in HBsAg-negative/HBcAb-positive patients with HIV infection treated with direct-acting antivirals for HCV: A retrospective study 57
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 55
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy 55
Hepatitis A virus in a medical setting in Madagascar: a lesson for public health 52
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 46
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 32
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir 22
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir. 18
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. 17
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 17
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir 15
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. 15
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 3
Totale 6.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.330
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.536 210 41 14 94 151 154 184 203 229 115 64 77
2020/2021852 188 62 27 28 28 56 7 36 111 44 37 228
2021/20221.375 71 75 66 147 103 62 31 107 57 230 252 174
2022/20231.577 142 231 59 193 138 96 38 100 271 57 171 81
2023/2024404 25 66 39 52 31 81 19 24 9 29 21 8
2024/202572 72 0 0 0 0 0 0 0 0 0 0 0
Totale 6.376